Pharmsynthez Share Price

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS Other stock markets 08/07/2022			5-day change	1st Jan Change
4.505 ^RUB	+10.15%		-.--%	-

02/08	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2026	CI
02/06	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Companyâ€™s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
LIFE Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	135.61Cr 11TCr 117.52Cr 110.01Cr 100.38Cr 188.9Cr 13TCr 192.07Cr 1.29TCr 505.41Cr 6.47TCr 509.16Cr 498.06Cr 22TCr	P/E 2021	-2.42x	P/E 2022	-6.53x
Enterprise Value	209.23Cr 17TCr 181.32Cr 169.74Cr 154.88Cr 291.45Cr 20TCr 296.35Cr 1.99TCr 779.82Cr 9.99TCr 785.59Cr 768.48Cr 33TCr	EV / Sales 2021	5.43x	EV / Sales 2022	5.51x
Free-Float	95.22%	Yield 2021 *	-	Yield 2022	-

02/08	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2026	CI
02/06	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI
27/11	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
29/25/29	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/23/28	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023	CI
19/23/19	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
19/23/19	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	CI
08/22/08	Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation	CI
28/22/28	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
12/21/12	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021	CI
16/21/16	Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez	CI
14/21/14	Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure	MT

5 years	2.64		7
10 years	2.64		18.75

Manager	Title	Age	Since
Petr Vladimirovich Kruglyakov CEO	Chief Executive Officer	48	01/01/2014
Alexey Shafranov DFI	Director of Finance/CFO	47	-
Dmitriy Nikolayevich Poznyak CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dmitriy Genkin CHM	Chairman	57	01/01/2005
Indrek Kasela BRD	Director/Board Member	54	01/01/2007
Steve Gorelik BRD	Director/Board Member	47	01/01/2007

Pharmsynthez Share Price

Stocks

LIFE

RU000A0JR514

Pharmaceuticals

Valuation: Pharmsynthez

Latest news : Pharmsynthez

Quotes and Performance

Course Extremes

Managers and Directors: Pharmsynthez

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHARMSYNTHEZ	+10.15%	-.--%	-.--%	-.--%	2.53Cr
ELI LILLY AND COMPANY	-1.37%	+8.90%	+91.28%	+130.00%	1,08300Cr
JOHNSON & JOHNSON	-0.77%	+1.91%	+49.46%	+49.44%	63TCr
ABBVIE INC.	+0.85%	+2.58%	+25.90%	+64.34%	44TCr
ROCHE HOLDING AG	-0.77%	+3.13%	+49.78%	+39.13%	36TCr
NOVARTIS AG	-0.73%	+1.01%	+31.08%	+38.64%	29TCr
ASTRAZENECA PLC	-0.72%	+0.89%	+7.32%	+7.38%	25TCr
AMGEN INC.	-0.70%	+6.23%	+45.32%	+57.82%	22TCr
NOVO NORDISK A/S	-1.76%	-0.13%	-4.77%	-50.50%	21TCr
GILEAD SCIENCES, INC.	+2.04%	+0.38%	+12.70%	+69.71%	17TCr
Average	+0.77%	+1,497.58%	+30.81%	+40.60%	36.59TCr
Weighted average by Cap.	-0.56%	+1,332.61%	+49.63%	+66.05%

	2021	2022
Net sales	44Cr 3.62TCr 38Cr 36Cr 32Cr 61Cr 4.18TCr 62Cr 416.97Cr 163.37Cr 2.09TCr 164.58Cr 160.99Cr 6.98TCr	38Cr 3.13TCr 33Cr 31Cr 28Cr 53Cr 3.62TCr 54Cr 361.17Cr 141.51Cr 1.81TCr 142.55Cr 139.45Cr 6.05TCr
Net income	-70Cr -5.76TCr -60Cr -57Cr -52Cr -97Cr -6.65TCr -99Cr -663.56Cr -259.98Cr -3.33TCr -261.91Cr -256.2Cr -11TCr	-21Cr -1.71TCr -18Cr -17Cr -15Cr -29Cr -1.98TCr -29Cr -197.38Cr -77Cr -990.57Cr -78Cr -76Cr -3.3TCr
Net Debt	69Cr 5.72TCr 60Cr 56Cr 51Cr 97Cr 6.61TCr 98Cr 659.14Cr 258.25Cr 3.31TCr 260.17Cr 254.5Cr 11TCr	74Cr 6.08TCr 64Cr 60Cr 54Cr 102.56Cr 7.02TCr 104.28Cr 700.35Cr 274.4Cr 3.51TCr 276.43Cr 270.41Cr 12TCr